Here are five key notes:
1. NuVasive will pay $13.8 million, including fees, to the United States to resolve the matter.
2. NuVasive does not anticipate entering into a corporate integrity agreement with the OIG related to the settlement.
3. It could take months to finalize the written statement agreement.
4. Since being issued the subpoena, the company has cooperated fully with the inquiry and responded to government concerns.
5. The resolution avoids the time and expenses of a possibly lengthy litigation process.
More articles on orthopedic devices:
Clinical trials, team growth, IPO—8 key notes on Bone Therapeutics’ 2014
Mazor Robotics’ guidance system reaches 10k milestone: 5 observations
10 key trends in the global orthopedic trauma market
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
